BMC Research Notes (Nov 2020)

A snapshot of Plasmodium falciparum malaria drug resistance markers in Sudan: a pilot study

  • Nouh S. Mohamed,
  • Hanadi Abdelbagi,
  • Hussam A. Osman,
  • Abdallah E. Ahmed,
  • Alaa M. Yousif,
  • Yusraa B. Edris,
  • Eman Y. Osman,
  • Aahd R. Elsadig,
  • Emmanuel E. Siddig,
  • Madinna Mustafa,
  • Ammar A. Mohammed,
  • Yousif Ali,
  • Maha M. Osman,
  • Mohamed S. Ali,
  • Rihab A. Omer,
  • Ayman Ahmed,
  • Carol H. Sibley

DOI
https://doi.org/10.1186/s13104-020-05363-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Objectives Malaria infection is still known to be a worldwide public health problem, especially in tropical and sub-tropical African countries like Sudan. A pilot study conducted to describe the trend of P. falciparum drug resistance markers in 2017–2018 in comparison to CQ and AS/SP eras in Sudan. The Pfcrt, Pfmdr-1, Pfdhfr, and Pfdhps genes were investigated. Data deposited by the worldwide antimalarial resistance network was consulted, and the molecular markers previously reported from Sudan were analyzed. Results Drug molecular markers analysis was successfully done on 20 P. falciparum isolates. The Pfcrt K76 showed high frequency; 16 (80%). For the Pfmdr-1, 9 (45%) isolates were carrying the N86 allele, and 11 (55%) were 86Y allele. While the Y184F of the Pfmdr-1 showed a higher frequency of 184F compared to Y184; 16 (80%) and 4 (20%), respectively. In the Pfdhfr, 51I allele showed higher frequency compared to N51; 18 (90%) and 2 (10%), respectively. For S108N, 18 (90%) were 108 N and 2 (10%) were S108. In the Pfdhps, all isolates were carrying the mutant alleles; 437G and 540E. The frequency distribution of the Pfcrt, Pfmdr-1, Pfdhfr, Pfdhps was significantly different across the whole years in Sudan.

Keywords